GlassScriptPhysician profile
Manuel Rosales
NPI 1487656740
$12,009.51
in general payments reported to CMS, 2019-2025
41 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,176 · 2020: $1,595 · 2021: $1,586 · 2022: $1,673 · 2023: $1,990 · 2024: $1,585 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,930 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,929.95 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,296.18 | 2019-2025 | Wegovy, Saxenda, Ozempic |
| Lilly USA, LLC | $1,445.40 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $1,203.18 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $950.06 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $937.31 | 2021-2025 | Vraylar |
| Pfizer INC. | $632.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $538.55 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $429.76 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $427.19 | 2019-2022 | |
| Amgen INC. | $308.74 | 2019-2025 | Repatha, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $289.08 | 2019-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $275.86 | 2019-2022 | |
| Daiichi Sankyo INC. | $195.58 | 2019-2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.09 | 2024-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $189.29 | 2023-2025 | Cologuard Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Rosales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.